Observational Prospective Registry of the Efficacy, Safety, and Adherence to Therapy of Infergen (Interferon Alfacon 1) in Patients Chronically Infected With Hepatitis C Virus

Trial Profile

Observational Prospective Registry of the Efficacy, Safety, and Adherence to Therapy of Infergen (Interferon Alfacon 1) in Patients Chronically Infected With Hepatitis C Virus

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2015

At a glance

  • Drugs Interferon alfacon-1 (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms REACH-SVR
  • Sponsors Kadmon Pharmaceuticals; Three Rivers Pharmaceuticals
  • Most Recent Events

    • 02 Sep 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 23 May 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top